These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 667820)

  • 1. Effect of progressive neoplastic growth on the decarboxylation of DL-[1-14C]ornithine by lymphocytes from C3H/He tumor hosts.
    Vaage J; Agarwal S; Reinertsen JL
    Cancer Res; 1978 Aug; 38(8):2253-8. PubMed ID: 667820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous tumor growth factor indicated by increased ornithine decarboxylase activity in malignant cells treated with host serum ascites fluid.
    Vaage J; Agarwal S
    Cancer Res; 1979 May; 39(5):1511-7. PubMed ID: 427794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of retinoic acid and juvenile hormone on the induction of ornithine decarboxylase activity by 12-O-tetradecanoylphorbol-13-acetate.
    Kensler TW; Verma AK; Boutwell RK; Mueller GC
    Cancer Res; 1978 Sep; 38(9):2896-9. PubMed ID: 679197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressive factors in ascitic fluids and sera of mice bearing ascites tumors.
    Elleman CJ; Eidinger D
    J Natl Cancer Inst; 1977 Sep; 59(3):925-31. PubMed ID: 894749
    [No Abstract]   [Full Text] [Related]  

  • 5. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC; Prager MD
    Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
    Luo JC; Toyoda M; Shibuya M
    Cancer Res; 1998 Jun; 58(12):2594-600. PubMed ID: 9635584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Halothane-induced suppression of cell-mediated immunity in normal and tumor-bearing C3Hf/He mice.
    Lewis RE; Cruse JM; Hazelwood J
    Anesth Analg; 1980 Sep; 59(9):666-71. PubMed ID: 7191225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A factor responsible for increases in ornithine decarboxylase activity in the livers of tumor-bearing mice.
    Noguchi T; Kashiwagi A; Tanaka T
    Cancer Res; 1976 Nov; 36(11 Pt 1):4015-22. PubMed ID: 975047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state.
    Tada T; Ohzeki S; Utsumi K; Takiuchi H; Muramatsu M; Li XF; Shimizu J; Fujiwara H; Hamaoka T
    J Immunol; 1991 Feb; 146(3):1077-82. PubMed ID: 1671050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrasting effects of activated and nonactivated macrophages and macrophages from tumor-bearing mice on tumor growth in vivo.
    Gabizon A; Leibovich SJ; Goldman R
    J Natl Cancer Inst; 1980 Nov; 65(5):913-20. PubMed ID: 6933261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on different stages in host-tumor relationship. 1. Differences in the behavior in vitro of ascites cells and lymphocytes derived from mice in early and later stages of tumor growth.
    Pikovski MA
    Isr J Med Sci; 1973 Feb; 9(2):136-44. PubMed ID: 4696151
    [No Abstract]   [Full Text] [Related]  

  • 12. Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum.
    Newberry WM; Sanford JP
    J Clin Invest; 1971 Jun; 50(6):1262-71. PubMed ID: 5578233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
    Strauss G; Gückel B; Wallwiener D; Moldenhauer G
    Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ornithine decarboxylase activity in malignant tumors].
    Siatkin SP; Berezov TT
    Vopr Med Khim; 1980; 26(1):121-4. PubMed ID: 7368616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host endocrine responses during tumor growth.
    Besedovsky H; del Rey A; Normann SJ
    Prog Clin Biol Res; 1989; 288():203-13. PubMed ID: 2654951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective serum effects in tumor immunity.
    Vaage J
    Isr J Med Sci; 1976; 12(4-5):334-43. PubMed ID: 939693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the mitogen response of lymphoid cells with progressive tumor growth.
    Gillette RW; Boone CW
    Cancer Res; 1975 Dec; 35(12):3774-9. PubMed ID: 1081429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of lymphocyte trapping by cell-free ascitic fluids cultivated in syngeneic mice.
    Mongini PK; Rosenberg LT
    J Immunol; 1975 Feb; 114(2 Pt 1):650-4. PubMed ID: 1120902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of the inhibition by retinoids of tumor promoter-induced mouse epidermal ornithine decarboxylase activity and of skin tumor promotion.
    Verma AK; Shapas BG; Rice HM; Boutwell RK
    Cancer Res; 1979 Feb; 39(2 Pt 1):419-25. PubMed ID: 761215
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential effect of interferon on DNA synthesis, 2-deoxyglucose uptake and ornithine decarboxylase activity in 3T3 cells stimulated by polypeptide growth factors and tumor promotors.
    Sreevalsan T; Rozengurt E; Taylor-Papadimitriou J; Burchell J
    J Cell Physiol; 1980 Jul; 104(1):1-9. PubMed ID: 6160162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.